The CLLSA has sent in a submission to NHS England (NHSE) in colaboration with Leukaemia Care.
The letter is attached below.
Living with a long-term incurable blood cancer presents many people with enormous physical and emotional pressures. We are grateful to Professor Tanya Byron for highlighting these issues in The Times.
European Haematology Association
Type: Poster Presentation
Presentation during EHA23: On Friday, June 15, 2018 from 17:30 - 19:00
Location: Poster area
STOCKHOLM — Final results from the phase 3 CLL11 trial confirm the superiority of the newer anti-CD20 monoclonal antibody drug obinutuzumab (Gazyva) compared to the older agent rituximab (Rituxan); both agents are from the same manufacturer, Roche, which sponsored the study.
CLLSA HeathUnlocked post with update on Flair trial - This is a locked post so you will need to be registered with HeathUnlocked to read. If you are interested in CLL then this is a valuable source of reliable information with over 8000 members.
On June 8, 2018, the U.S. Food and Drug Administration (FDA) approved the use of venetoclax (VENCLEXTA) for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy.
This approval is based on data from a clinical trial evaluating venetoclax in combination with rituximab (Rituxan). The trial compared venetoclax plus rituximab with bendamustine plus rituximab in CLL patients who had received at least one prior line of therapy.
The UK CLL Forum is comprised of the most eminent CLL doctors in the UK. They have written to The Times newspaper, following up on the original article which appeared last Saturday. An additional article appeared in the Times today.
Here's the link to the article: thetimes.co.uk/article/nhs-...
And this is the letter: